Arjun Agarwal, serving as Senior Vice President of Finance at Oruka Therapeutics, Inc. (NASDAQ: ORKA), has completed a series of equity transactions involving the company's common stock. The activities, which spanned June 12 and June 15, 2026, included the sale of shares valued at approximately $687,035 and the exercise of stock options. These movements highlight the execution of structured financial planning mechanisms within the context of the company's ongoing operational and clinical milestones.
On June 12, 2026, Agarwal sold a total of 9,459 shares of Oruka Therapeutics common stock. The sales were conducted through multiple transactions with weighted average prices ranging from $68.3419 to $70.3392 per share. The specific breakdown of these sales includes 1,859 shares sold at prices between $67.87 and $68.71, 4,340 shares sold at prices between $69.07 and $70.06, and 3,260 shares sold at prices between $70.07 and $70.86. These transactions were executed pursuant to a Rule 10b5-1 trading plan that was established on February 11, 2026. This pre-arranged framework allows for the systematic execution of trades regardless of internal market movements.
Subsequently, on June 15, 2026, Agarwal sold an additional 395 shares at a price of $69.69 per share. This specific transaction was part of Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure. The primary purpose of this mechanism is to satisfy tax withholding obligations related to the vesting of restricted stock units. This type of automatic sale is a standard operational procedure for equity compensation management.
In conjunction with the sales on June 12, Agarwal acquired 9,459 shares of common stock through the exercise of employee stock options. The total value of these acquisitions was approximately $150,175. The acquisition included 8,000 shares obtained at an exercise price of $12.50 per share, with the option vesting monthly from January 1, 2025. Additionally, 1,459 shares were acquired at an exercise price of $34.39 per share, with this option vesting monthly from January 1, 2026. Following these transactions, Agarwal directly owns 16,899 shares of Oruka Therapeutics common stock. This total includes 888 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026.
These executive transactions occur against a backdrop of significant corporate developments for Oruka Therapeutics. The company recently announced an upsized public offering, pricing 9,660,000 shares of common stock at $72.50 per share. This offering is expected to generate approximately $700.4 million in gross proceeds. The capital raise follows the announcement of positive interim results from the EVERLAST-A Phase 2a trial. This trial evaluated the efficacy and safety of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The results indicated that 63.5% of participants achieved PASI 100 at Week 16.
Furthermore, Oruka Therapeutics has amended its IL-23 license agreement with Paragon Therapeutics. This amendment allows for expanded development opportunities in both combination and monotherapy treatments. Analyst firms have responded positively to these developments. H.C. Wainwright reiterated a Buy rating and increased its price target to $120, citing the successful trial data. Piper Sandler also reaffirmed an Overweight rating with a $180 price target, highlighting the strategic importance of the license amendment.